Results 151 to 160 of about 113,306 (267)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Processing of DNA Topoisomerase II-DNA-Protein Crosslinks Associated With Anticancer Drugs. [PDF]

Genes Cells
Sakasai R, Iwabuchi K.
europepmc   +1 more source

Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells. [PDF]

Oncotarget, 2023
Juchem ALM, Trindade C, da Silva JB, Machado MDS, Guecheva TN, Rocha JC, Saffi J, de Oliveira IM, Henriques JAP, Escargueil A.   +9 more
europepmc   +1 more source

Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC

Cancer Science, Volume 117, Issue 5, Page 1273-1285, May 2026.
Our work makes the proof of concept that there is a clinical benefit to target both PRMT1 and PRMT5 to maximize the anti‐tumoral effect of chemotherapy in triple negative breast cancer. ABSTRACT Patients with triple‐negative breast cancer (ER−, PR−, and HER2−) are routinely treated with chemotherapies that induce DNA damage.
Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El‐Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis, Coralie Poulard, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer   +13 more
wiley   +1 more source

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. [PDF]

J Clin Invest
Xu R, Wang D, Ma G, Yuan X, Chu Q, Fan S, Zhang R, Du P, Jia S, Leal TA, Ramalingam SS, Chen Z, Sun SY.   +12 more
europepmc   +1 more source

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source

Patulin and Xestoquinol are inhibitors of DNA topoisomerase 1. [PDF]

Proc Natl Acad Sci U S A
Tumini E, Wellinger RE, Herrera-Moyano E, Navarro-Cansino P, García-Rubio M, Salas-Lloret D, Losada A, Muñoz-Alonso MJ, Gaillard H, Luna R, Aguilera A.   +10 more
europepmc   +1 more source

Mutation in MSH5 Causes Primary Ovarian Insufficiency and Successful Therapeutic Intervention by In Vitro Fertilisation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Primary ovarian insufficiency (POI) is a genetically heterogeneous disorder characterised by cessation of menstruation before the age of 40 years with elevated levels of follicle‐stimulating hormone. Germline variants in the MSH5 gene cause POI. In this study, we investigated a Han Chinese family with POI.
Bin Mao, Lili Zhang, Xiaodong Zhao, Xiaojuan Xu, Hongfang Liu, Dexiao Song, Peiqiang Li, Santasree Banerjee, Xiaoling Ma, Yongxiu Yang   +9 more
wiley   +1 more source

Emerging Techniques for the Extraction and Enzymatic Hydrolysis of Plant Proteins From Waste: An Integrative Review

Journal of Food Process Engineering, Volume 49, Issue 5, May 2026.
The graphical abstract presents plant protein sources and emerging extraction and enzymatic hydrolysis techniques, highlighting innovative technologies to increase yield, preserve nutritional quality, and generate hydrolysates and bioactive peptides with potential health benefits and sustainable industrial applications. ABSTRACT The growth of the world
Lara Louzada Aguiar, Roberta Soares Cabral, Vinícius Serafim Coelho, Bruna Vieira Nunes, Viviane Dias Medeiros Silva, Gabriel Barbosa de Oliveira, Renata Adriana Labanca, Julio Onesio‐Ferreira Melo, Raquel Linhares Bello de Araújo   +8 more
wiley   +1 more source

The DNA helicase RTEL1 is involved in the repair of replicative DNA damage independently of the alternative end joining and the DNA–protein cross‐link repair pathways in Arabidopsis

The Plant Journal, Volume 126, Issue 3, May 2026.
SUMMARY Recent studies indicate that the Fe–S DNA helicase RTEL1 plays an important role in replicative DNA repair in plants. Since non‐homologous end joining (NHEJ) and DNA–protein cross‐link (DPC) repair also protect DNA replication in Arabidopsis, we set out to further define the interactions of RTEL1 and these pathways by analyzing double mutants ...
Lara Goldkuhle, Laura Lechner, Niklas Capdeville, Annika Dorn, Holger Puchta   +4 more
wiley   +1 more source